4D Molecular Therapeutics, Inc. Stock News

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth

With its strong focus on product design and development excellence, as evidenced by its sustained success in IND clearance, 4D Molecular Therapeutics is a promising biotech company with significant gr

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for

EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT'), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targe

FDMT is an undercovered gene therapy developer. It claims certain competitive differences for its vector delivery platform.

Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.

Recent analyst upgrades suggest these stocks can triple your money or better.

4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth

EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -11.54% and 94.60%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for t

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted g

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for

4D Molecular Therapeutics, Inc. (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.